Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The ...

Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...

After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

Appeals court upholds J&J win blocking Mylan's generic version of schizophrenia drug Invega Trinza, protecting patent for ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision.

CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...

Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication ...

Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects ...

DBV Technologies could get $306M for peanut allergy patch; Eisai sells Pariet rights in China; Palatin reports UC trial data; ...

Alpha Lee announced a Zika virus-fighting molecule at a chemistry meeting, but later learned his $67M federal funding was cut due to pandemic's end, affecting multiple antiviral research programs.

Milestone Pharmaceuticals' nasal spray etripamil fails FDA approval for PSVT due to CMC issues, sending shares down 60%. Drug's efficacy and safety weren't questioned.